Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 2/2015

01-06-2015 | Case Report

Primary Hepatic Lymphoma: Features of a Puzzling Disease

Authors: Magalí Chahdi Beltrame, Martín De Santibañes, Victoria Ardiles, Oscar Mazza, Juan Pekolj, Eduardo De Santibañes, Rodrigo Sánchez Clariá

Published in: Journal of Gastrointestinal Cancer | Issue 2/2015

Login to get access

Excerpt

Primary hepatic lymphoma (PHL) is a very rare liver tumor. It is described as a lymphoma localized and limited to the liver without extrahepatic involvement [1], and represents about 0.016 % of all non-Hodgkin lymphoma cases [2]. …
Literature
1.
Caccamo D, Pervez NK, Marchevsky A. Primary lymphoma of the liver in the acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1986;110(6):553–5.PubMed
2.
Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29(1):252–60.CrossRefPubMed
3.
Yang X, Tan W, Yu W, Shi S, Wang Y, Zhang Y, et al. Diagnosis and surgical treatment of primary hepatic lymphoma. World J Gastroenterol. 2010;16(47):6016–9.PubMedCentralPubMed
4.
Bouliaris K, Christodoulidis G, Koukoulis G, Mamaloudis I, Ioannou M, Bouronikou E, et al. A primary hepatic lymphoma treated with liver resection and chemotherapy. Case Rep Surg. 2014;2014:749509.PubMedCentralPubMed
5.
6.
Page RD, Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer. 2001;92(8):2023–9.CrossRefPubMed
7.
Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ HM, Kirgner I, et al. Serum CA 125 as a prognostic factor in non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(10):1733–8.CrossRefPubMed
8.
Gutiérrez A, Martínez-Serra J, Barceló B, Sampol A, Viñas L, González G, et al. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value. Int J Lab Hematol. 2010;32(6 Pt 2):582–9.CrossRefPubMed
9.
Ojha RP, Brown LM, Felini MJ, Singh KP, Thertulien R. Addressing uncertainty regarding the utility of carbohydrate antigen-125 as a prognostic marker in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(9):1754–7.CrossRefPubMed
10.
Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med. 1994;121(9):633–40.CrossRefPubMed
11.
12.
Steller EJ, van Leeuwen MS, van Hillegersberg R, Schipper ME, Rinkes IHB, Molenaar IQ. Primary lymphoma of the liver—a complex diagnosis. World J Radiol. 2012;4(2):53–7.CrossRefPubMedCentralPubMed
13.
Abelev GI, Karamova ER, Bragina EG, Andreeva NE, Kruglova GV. Immuno-isotachophoretic determination of monoclonal immunoglobulin light chains produced by neoplastic B-cells: use in diagnosis, monitoring and detection of residual disease. Int J Cancer. 1990;46(3):351–5.CrossRefPubMed
14.
15.
Takeuchi N, Naba K. Primary hepatic lymphoma is difficult to discriminate from a liver abscess. Case Rep Gastrointest Med. 2014;2014:925307.PubMedCentralPubMed
16.
Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L, Sanz-rodriguez C, and Cabanillas F. “Favorable Outcome after Combination Chemotherapy,” Am Cancer Soc, pp. 10–15, 1995.
17.
Mastoraki A, Stefanou MI, Chatzoglou E, Danias N, Kyriazi M, Arkadopoulos N, et al. Primary hepatic lymphoma: dilemmas in diagnostic approach and therapeutic management. Indian J Hematol Blood Transfus. 2014;30(3):150–4.CrossRefPubMed
18.
Eidt S, Nebeling M, Pohl C, Siedek M. [Neoadjuvant chemotherapy of primary hepatic non-Hodgkin’s lymphoma]. Med Klin (Munich). 2003;98(2):96–9.CrossRef
19.
Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol. 2005;53(3):199–207.CrossRefPubMed
Metadata
Title
Primary Hepatic Lymphoma: Features of a Puzzling Disease
Authors
Magalí Chahdi Beltrame
Martín De Santibañes
Victoria Ardiles
Oscar Mazza
Juan Pekolj
Eduardo De Santibañes
Rodrigo Sánchez Clariá
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9694-3

Other articles of this Issue 2/2015

Journal of Gastrointestinal Cancer 2/2015 Go to the issue

Original Research

Female Sex Hormone Receptors in Gallbladder Cancer

Original Research

Epidemiology and Risk Factors for Exocrine Pancreatic Cancer in a Northern African Population

Letter to the Editor

Hepatobiliary Cystadenocarcinoma of the Liver with Features of Ductal Plate Malformations

Case Report

Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?

Case Report

Small-for-Size Liver Syndrome: a Case Series with a Proposal for Management Based on Portal Flow Modulation

Original Research

Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits